Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma
Figure 2
Quantification of hypoxic and necrotic areas in tumor xenografts treated with TekdeltaFc and LDM CTX. (a) Representative low (5x, left) and high (20x, right) magnification images of hypoxia immunostaining for Hypoxyprobe adducts and tissue necrosis in tumor sections. Dark brown areas are hypoxic (arrow), light brown areas are viable tumor (arrowhead), and areas lacking brown reaction product and containing degraded nuclei are necrotic tissue (asterisk). (b) Quantification of the mean percent viable tissue, hypoxia, necrosis, or hypoxia and necrosis in each treatment group, showing significant differences in proportions of necrotic, and necrotic plus hypoxic areas in LDM-CTX-treated tumors compared to control and combination (*).
